OOIR: Observatory of International Research

Papers

(The H4-Index of Expert Opinion on Drug Safety is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Novel insights into post-marketing AEs associated with bempedoic acid: a comprehensive analysis utilizing the FAERS database	86
Drug-induced hepatitis B virus reactivation: insights from FAERS database analysis	69
Adverse event profiles of drug-induced decreased libido: an assessment of the US food and drug administration Adverse Event Reporting System	68
Resistance to hedgehog inhibitors in basal cell carcinoma: strategies to adopt	59
Assessment of adverse events of the novel antiepileptic drug lamotrigine: a real-world pharmacovigilance study based on FAERS	53
Adverse events in patients with cardiovascular disease taking proton pump inhibitors	50
The role of artificial intelligence in pharmacovigilance for rare diseases	44
Exploration and evaluation of adverse event signals of droxidopa based on the FAERS database	42
Safety profile of isocitrate dehydrogenase inhibitors in cancer therapy: a pharmacovigilance study of the FDA Adverse Event Reporting System	39
Exploration of cardiac adverse events associated with relugolix and degarelix: a multi-center pharmacovigilance study based on the FAERS database	38
Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile	36
An updated safety review of Hidradenitis Suppurativa treatment options	36
The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism	34
Thromboembolic events in younger women exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines	33
Infectious events in patients with alopecia areata treated with JAK inhibitors: low burden and minimal impact on persistence in treatment	33
Comparison of adverse events of poly adenosine diphosphate ribose polymerase inhibitors in patients with ovarian cancer using the United States Food and Drug Administration Adverse Event Reporting Sys	32
Mechanism and clinical utility of abatacept in the treatment of rheumatoid arthritis	29
An update on the cognitive safety of antimuscarinics in the treatment of overactive bladder	29
The safety of phthalate-containing medications used during pregnancy	27
Assessment of adverse events related to anti-interleukin-6 receptor monoclonal antibodies using the FDA adverse event reporting system: a real-world pharmacovigilance study	25
Safety assessment of brexanolone in the FAERS database: real adverse event analysis and discussion of side effects	24
Long-term safety of ketamine and esketamine in treatment of depression	24
A real-world pharmacovigilance study of QT interval prolongation and Torsades de Pointes associated with CDK4/6 inhibitors in breast cancer patients: findings from the FDA adverse event reporting syst	23
Gastrointestinal and cardiovascular adverse events associated with NSAIDs	23